{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-218225","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2026-05-12T12:00:17+00:00","discovered_at":"2026-05-12T12:05:00.280224+00:00","generated_at":"2026-05-12T12:19:23.650329+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PMV Pharma Q1 net loss $18M; rezatapopt NDA for ovarian cancer targeted for Q1 2027","bullets":["Cash and securities $93.5M at March 31, 2026; net cash used in operations $19.7M for Q1.","Net loss $18M for Q1 2026 vs $17.4M in Q1 2025; R&D expenses decreased to $15.3M.","Confirmed ORR 44% (32/72) for rezatapopt in platinum-resistant/refractory TP53 Y220C ovarian cancer from SGO April 2026.","FDA granted Orphan Drug Designation for rezatapopt in TP53 Y220C positive ovarian cancer.","Phase 1 results published in NEJM; NDA submission planned in Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-218225","json":"https://secwatch.observer/filing/0001193125-26-218225.json","markdown":"https://secwatch.observer/filing/0001193125-26-218225.md","text":"https://secwatch.observer/filing/0001193125-26-218225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/0001193125-26-218225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/pmvp-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T12:19:23.650329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"37490a5c879039c8dec7824841df9925d11a4e12","claim":"PMV Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"Net loss for the quarter ended March 31, 2026, was $18 million compared to $17.4 million for the quarter ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/0001193125-26-218225-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"37490a5c879039c8dec7824841df9925d11a4e12","claim":"PMV Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"PMV Pharma ended the first quarter with $93.5 million in cash, cash equivalents, and marketable securities, compared to $112.9 million as of December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526218225/0001193125-26-218225-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}